Wall Street Zen upgraded shares of ArriVent BioPharma (NASDAQ:AVBP – Free Report) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.
Several other brokerages also recently issued reports on AVBP. Citigroup lowered their price objective on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Guggenheim upped their target price on shares of ArriVent BioPharma from $18.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ArriVent BioPharma in a research note on Thursday. Jefferies Financial Group set a $18.00 target price on shares of ArriVent BioPharma in a research note on Tuesday, October 6th. Finally, Oppenheimer reissued an “outperform” rating and set a $25.00 price target on shares of ArriVent BioPharma in a report on Monday, October 26th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.
View Our Latest Analysis on AVBP
ArriVent BioPharma Trading Down 11.1%
AVBP stock opened at $11.56 on Friday. The company has a market capitalization of $597.88 million, a P/E ratio of -3.21 and a beta of 1.66. ArriVent BioPharma has a twelve month low of $11.36 and a twelve month high of $35.83. The business has a 50 day simple moving average of $20.97 and a 200-day simple moving average of $26.35.
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The business had revenue of $5.00 million during the quarter, compared to analyst estimates of $0.80 million. Research analysts predict that ArriVent BioPharma will post -3.81 EPS for the current fiscal year.
Hedge Funds Weigh In On ArriVent BioPharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Montanova Capital LLC increased its stake in ArriVent BioPharma by 2.6% in the 2nd quarter. Montanova Capital LLC now owns 4,515,531 shares of the company’s stock valued at $156,870,000 after buying an additional 114,448 shares during the period. Hhlr Advisors LTD. acquired a new stake in shares of ArriVent BioPharma in the 2nd quarter worth $136,498,000. BlackRock Inc. acquired a new stake in shares of ArriVent BioPharma in the 2nd quarter worth $112,919,000. General Catalyst Group Management LLC purchased a new stake in shares of ArriVent BioPharma in the second quarter valued at about $51,929,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of ArriVent BioPharma by 29.7% in the third quarter. Goldman Sachs Group Inc. now owns 1,107,094 shares of the company’s stock valued at $33,523,000 after acquiring an additional 253,371 shares in the last quarter. 9.48% of the stock is currently owned by hedge funds and other institutional investors.
About ArriVent BioPharma
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.
Further Reading
- Five stocks we like better than ArriVent BioPharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
